在退化型跨导管生物假体 (TAV-in-TAV) 中进行重置跨导管大动脉置换
Juan Sánchez-Ceña1, Lluis Asmarats1, Chi Hion Pedro Li1
1Hospital Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Barcelona, Spain.
Expert review of cardiovascular therapy
|October 10, 2023
概括
随着跨导管大动脉置换 (TAVR) 扩展到年轻患者中,生物假肢失效将增加. 本综述涵盖了对退化门的重复TAVR和扩散剂,重点是规划和结果.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 假肢退化症 假肢退化症
背景情况:
- 通过导管的大动脉置换 (TAVR) 越来越多地用于年轻的低风险患者.
- 目前的跨导管生物假体的寿命可能比患者的预期寿命短.
- 这将导致对失败的TAVR设备进行干预的需求日益增加.
研究的目的:
- 提供对退化生物假体的重复TAVR进行最新的审查.
- 专注于手术前的规划,TAVR-in-TAVR中冠状动脉反应的挑战,以及 TAVR 解释与重复的结果.
主要方法:
- 关于TAVR设备退化现有文献的综述.
- 对管理失败的跨导管生物假体策略的分析.
- 讨论了外科实验和重复TAVR手术的结果.
主要成果:
- 过导管生物假体的退化是一个新出现的临床问题.
- 修复TAVR和外科实验剂是管理故障设备的可行选择.
- 在TAVR-in-TAVR期间冠状动脉复发带来了特殊的挑战.
结论:
- 在初始TAVR期间,仔细选择患者和个性化植入至关重要.
- 与未来的TAVR-in-TAVR冠状动脉接触风险平衡心脏起器避免是必不可少的.
- 需要进行前性研究,比较重复TAVR和TAVR扩散剂.
相关概念视频
Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24
Mitral Stenosis III: Medical Management
12
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12


